Citadel Advisors
MLNT

Citadel Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Citadel Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-56,839
Closed -$30K – 10606
2019
Q4 		$30K Buy
56,839
+41,984
+283% +$102K ﹤0.01% 8872
2019
Q3 		$57K Sell
14,855
-16,259
-52% -$58.6K ﹤0.01% 8670
2019
Q2 		$207K Buy
31,114
+16,324
+110% +$62.1K ﹤0.01% 8143
2019
Q1 		$53K Sell
14,790
-363
-2% -$1.97K ﹤0.01% 8801
2018
Q4 		$60K Buy
15,153
+2,515
+20% +$32.2K ﹤0.01% 8441
2018
Q3 		$250K Sell
12,638
-2,158
-15% -$54.6K ﹤0.01% 7873
2018
Q2 		$469K Buy
14,796
+12,421
+523% +$447K ﹤0.01% 6475
2018
Q1 		$88K Sell
2,375
-1,373
-37% -$90.3K ﹤0.01% 7755
2017
Q4 		$296K Buy
+3,748
New +$277K ﹤0.01% 6490

Citadel Advisors's MLNT Position: Q1 2020 in Review

Citadel Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 56,839 shares — an estimated $30K sold.

Citadel Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $469K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Citadel Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Citadel Advisors sold 56,839 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $30K.
  • Citadel Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Citadel Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $469K in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.